Elanco Animal Health Incorporated Class Action Lawsuit - ELAN

The filed complaint alleges that Elanco Animal Health Incorporated made materially false and/or misleading statements and/or failed to disclose that: (i) Zenrelia, a once-daily oral inhibitor for canine dermatology, was less safe than the Company had led investors to believe; (ii) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro, a broad spectrum parasiticide product for dogs; (iii) accordingly, the Company’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the ELAN class action lawsuit, you must have incurred a loss on shares of Elanco purchased during the class period listed above.

If you suffered a loss in Elanco during the relevant time frame or pursuant to the relevant offering(s), you have until December 6, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.